Brokerages predict that United Therapeutics Co. (NASDAQ:UTHR) will report earnings of $3.37 per share for the current quarter, according to Zacks. Five analysts have made estimates for United Therapeutics’ earnings, with the highest EPS estimate coming in at $4.34 and the lowest estimate coming in at $2.80. United Therapeutics posted earnings of $6.27 per share during the same quarter last year, which would suggest a negative year over year growth rate of 46.3%. The firm is expected to announce its next earnings results on Wednesday, October 24th.

According to Zacks, analysts expect that United Therapeutics will report full-year earnings of $13.71 per share for the current fiscal year, with EPS estimates ranging from $12.66 to $15.00. For the next fiscal year, analysts expect that the business will report earnings of $11.14 per share, with EPS estimates ranging from $8.08 to $13.59. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for United Therapeutics.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.57 by $1.41. The firm had revenue of $444.50 million during the quarter, compared to analyst estimates of $368.63 million. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The business’s quarterly revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.37 earnings per share.

A number of research analysts recently commented on the company. TheStreet raised United Therapeutics from a “c+” rating to a “b” rating in a report on Thursday, August 16th. BidaskClub raised United Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 11th. Zacks Investment Research raised United Therapeutics from a “hold” rating to a “buy” rating and set a $127.00 target price on the stock in a report on Saturday, July 7th. Wedbush set a $253.00 target price on United Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, Cowen reaffirmed a “hold” rating and set a $110.00 target price on shares of United Therapeutics in a report on Thursday, August 2nd. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $138.86.

NASDAQ:UTHR traded down $2.16 on Friday, hitting $123.92. 382,041 shares of the stock were exchanged, compared to its average volume of 429,416. United Therapeutics has a fifty-two week low of $100.57 and a fifty-two week high of $152.55. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.64 and a quick ratio of 4.35. The firm has a market capitalization of $5.57 billion, a PE ratio of 11.38, a P/E/G ratio of 28.86 and a beta of 1.28.

In other news, Director Richard Giltner sold 3,240 shares of the stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $129.38, for a total transaction of $419,191.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Judy D. Olian sold 600 shares of the stock in a transaction that occurred on Tuesday, June 12th. The stock was sold at an average price of $112.38, for a total value of $67,428.00. The disclosure for this sale can be found here. Insiders have sold a total of 7,080 shares of company stock worth $852,966 over the last quarter. Insiders own 8.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in UTHR. HL Financial Services LLC raised its position in shares of United Therapeutics by 40.2% during the 1st quarter. HL Financial Services LLC now owns 2,053 shares of the biotechnology company’s stock worth $231,000 after purchasing an additional 589 shares during the period. NuWave Investment Management LLC raised its position in shares of United Therapeutics by 13,112.5% during the 1st quarter. NuWave Investment Management LLC now owns 1,057 shares of the biotechnology company’s stock worth $116,000 after purchasing an additional 1,049 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of United Therapeutics by 0.7% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 125,363 shares of the biotechnology company’s stock worth $14,086,000 after purchasing an additional 933 shares during the period. Westpac Banking Corp raised its position in shares of United Therapeutics by 455.2% during the 1st quarter. Westpac Banking Corp now owns 13,975 shares of the biotechnology company’s stock worth $1,570,000 after purchasing an additional 11,458 shares during the period. Finally, DekaBank Deutsche Girozentrale raised its position in shares of United Therapeutics by 7.8% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 75,834 shares of the biotechnology company’s stock worth $8,454,000 after purchasing an additional 5,509 shares during the period. Institutional investors and hedge funds own 99.59% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Story: Asset Allocation, Balancing Your Investments

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.